FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
This article was originally published in The Tan Sheet
Executive Summary
An FDA final guidance on botanical drug products includes new language recommending that firms demonstrate "batch-to-batch consistency" for botanical drug candidates through the clinical development process prior to submitting an NDA
You may also be interested in...
FDA Botanical Review Team Clears Green Tea-Based Drug As First Approval
FDA's Botanical Review Team on Oct. 31 approved its first botanical drug, MediGene's Polyphenon E ointment
Questions Circle INDs; Industry Needs Guidance For Probiotics, Say Experts
FDA should consider issuing a guidance for probiotics similar to the 2004 industry guidance for botanical drugs, panelists said at a recent Drug Information Association conference
FDA Botanical Review Team Clears Green Tea-Based Drug As First Approval
FDA's Botanical Review Team on Oct. 31 approved its first botanical drug, MediGene's Polyphenon E ointment